Skip to content
Review Open access

Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis.

Oct 2026 · Journal of the National Cancer Institute · 0 citations
Medicine

TL;DR

ADCs efficacy in metastatic breast cancer was similar across age groups, though data in early-stage disease were limited, and insufficient age- and treatment-stratified toxicity reporting precludes meaningful safety assessment of ADCs in older adults with breast cancer.

Abstract

Background

: Antibody-drug conjugates (ADCs) have reshaped breast cancer treatment, yet their efficacy and toxicity in older adults (≥65 years) remain poorly characterized.

Methods

: We searched PubMed, Ovid MEDLINE, and Embase (Elsevier) through November 17, 2025 for phase 2 or 3 randomized trials comparing ADCs versus non-ADC therapies in metastatic or early-stage breast cancer. The primary analysis assessed progression-free survival (PFS) in metastatic disease and invasive disease-free survival (IDFS) in early-stage disease, stratified by age (≥65 vs. <65 years), using pooled hazard ratios (pHRs). Age-by-treatment interaction was assessed using the ratio of HRs. Secondary outcomes included overall survival (OS) and grade ≥3 adverse events (AEs).

Results

Of 3,045 records identified, 20 trials (14 metastatic, 6 early-stage; 13,055 participants, 18% aged ≥65 years) met inclusion criteria. In metastatic trials, ADCs improved PFS in both older (pHR, 0.64; 95% CI, 0.51-0.79) and younger participants (pHR, 0.58; 95% CI, 0.51-0.66), with no significant age-by-treatment interaction (pooled ratio of HRs, 1.10; 95% CI, 0.91-1.33). ADCs also improved OS in the metastatic setting, though no trial reported age-stratified OS. In early-stage trials, only two reported age-stratified IDFS, with discordant results precluding pooled analysis. Grade ≥3 AEs were reported across all trials, but only three provided age-stratified data, and none stratified AEs jointly by treatment arm and age.

Conclusion

ADC efficacy in metastatic breast cancer was similar across age groups, though data in early-stage disease were limited. Insufficient age- and treatment-stratified toxicity reporting precludes meaningful safety assessment of ADCs in older adults with breast cancer.

Read PDF

Similar papers

Review Open access Oct 2026

Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis

Purpose This systematic review and meta-analysis aimed to compare the efficacy and safety of antibody-drug conjugates (ADCs) vs. conventional chemotherapy in patients with triple-negative breast cancer (TNBC) and to provide evidence for clinical decision-making and guideline development. Methods We systematically searc...

Ken Wan, Meng-Xin Liu · 0 citations
Sep 2026

Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.

OBJECTIVE The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate...

L. F. Costa de Almeida, A. Cappellaro, M. Noronha et al. · 1 citation
Review Sep 2026

Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis.

BACKGROUND Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...

G. B. Silva, A. Simões, R. L. Nohmi et al. · 0 citations
Open access Sep 2026

Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?

Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...

A. Agbarya, N. S. Shrem, Asmah Miari et al. · 0 citations
Review Open access Oct 2026

Efficacy and safety of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis

Background Antibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) resistance. We evaluated their efficacy and safety in this setting. Methods PubMed, Embase,and the Cochrane Library were searched for pros...

Yi-Lin Chen, Shuai-Xuan Chen, Hang-Tian Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.